BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · IEX Real-Time Price · USD
30.86
+1.10 (3.70%)
At close: Mar 27, 2024, 4:00 PM
31.01
+0.15 (0.49%)
Pre-market: Mar 28, 2024, 8:08 AM EDT

BridgeBio Pharma Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 2023202220212020201920182017
Revenue
9.377.6569.728.2540.5600
Revenue Growth (YoY)
-88.02%11.38%745.14%-79.66%---
Cost of Revenue
2.453.433.1102.500
Gross Profit
6.8674.2166.68.2538.0600
Selling, General & Admin
150.59143.19192.21145.6894.3543.5913.3
Research & Development
455.71399.46451.02337.05209.95140.0730.56
Other Operating Expenses
7.9343.7700000
Operating Expenses
614.23586.42643.23482.73304.3183.6643.86
Operating Income
-607.37-512.2-576.63-474.48-266.24-183.66-43.86
Interest Expense / Income
81.2980.4446.7836.668.772.550.01
Other Expense / Income
-45.46-111.46-60.87-62.41-14.42-55.46-13.31
Pretax Income
-643.2-481.18-562.54-448.72-260.59-130.75-30.57
Net Income
-643.2-481.18-562.54-448.72-260.59-130.75-30.57
Shares Outstanding (Basic)
1631471441181056231
Shares Outstanding (Diluted)
1631471441181056231
Shares Change
10.39%2.16%22.34%12.27%70.15%101.86%-
EPS (Basic)
-3.95-3.26-3.90-3.80-2.48-2.12-1.00
EPS (Diluted)
-3.95-3.26-3.90-3.80-2.48-2.12-1.00
Free Cash Flow
-529.03-314.32-511.18-407.23-256.23-138.82-40.95
Free Cash Flow Per Share
-3.25-2.13-3.54-3.45-2.44-2.25-1.34
Gross Margin
73.71%95.58%95.53%100.00%93.84%--
Operating Margin
-6528.75%-659.65%-827.12%-5751.99%-656.41%--
Profit Margin
-6913.92%-619.70%-806.90%-5439.74%-642.47%--
Free Cash Flow Margin
-5686.62%-404.79%-733.23%-4936.74%-631.72%--
EBITDA
-551.39-388.8-504.31-407.53-250.96-128.2-30.55
EBITDA Margin
-5926.98%-500.72%-723.37%-4940.30%-618.75%--
Depreciation & Amortization
10.5311.9411.454.540.8600
EBIT
-561.91-400.75-515.76-412.07-251.82-128.2-30.55
EBIT Margin
-6040.13%-516.10%-739.80%-4995.38%-620.86%--
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).